Audit: QRS - Avoiding Fluoride for Health & Longevity of the ER frontmatter
Audit conducted on 10/08/2026 08:56 using AI4L / Grok 4
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 84 |
| Failed | 0 |
| N/A | 7 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Speculative tiers and conflicted IQ signal preserved. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Special populations not relabeled as contraindications. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | None of these appear in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | At-a-glance uses plain “cavity” per 7.4; body uses “caries”. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Marker/qualitative placeholders expanded to numbered spans as intended. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No mapped ER section is empty in a way that requires empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol and interaction labels match ER bold labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | duration quotes required (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: avoiding_fluoride_2026-0810-0641_Grok_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0810-0750 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Grok |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Grok 4 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | avoiding_fluoride_2026-0810-0641_Grok_QRS.html |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Avoiding Fluoride for Health & Longevity - Quick Reference Sheet |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 08/10/2026 from 2026-0810-0750 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Grok 4 |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | ER lists no absolute contraindications to avoidance; stop_items correctly empty. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | No items to format. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No items. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | No items. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation. |
| 8.7 | If no [stop_items] are present the section is left empty | 🟢 | stop_items span is empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All five ER interaction bullets present. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Severity tags and food/beverage examples preserved. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No ranking notation. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | From Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Water, toothpaste, diet sources. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Systemic load, thyroid markers, caries risk from Practical Considerations. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Systemic (enables high benefits), thyroid (medium), caries (main trade-off risk). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three aspects used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Remaining scope words match ER benefit titles (key facts), not added elaborations. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | Example-style parens stripped on low tier; “(conflicted)” preserves ER ⚠️ Conflicted marker without emoji (required by 1.2/1.3 and 4.4). |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers have content. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers have content. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 7 table biomarkers present. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 4 qualitative markers present. |
Issues 10/08/2026 08:56
Pass rate 100.00%. No issues found.
Issues 10/08/2026 08:48
- 7.4 — Specialist at-a-glance terms: at_a_glance uses “enamel mottling” and “remineralizing” (specialist dental terms) instead of plain-language alternatives a non-specialist would use unprompted.
Fixes 10/08/2026 08:48
- 7.4 — Specialist at-a-glance terms: Replaced “enamel mottling” with “enamel spotting” and “fluoride-free remineralizing toothpaste maintain enamel protection” with “fluoride-free enamel-protecting toothpaste keep teeth protected” (still 60 words).
Issues 10/08/2026 08:40
-
1.2 — Conflicted phrasing omitted: ER Expected Benefits marks childhood IQ decrement reduction as “Conflicted”; QRS
benefits_mediumstates the IQ claim without that cautious phrasing. -
1.3 — IQ benefit strengthened: Dropping the ER’s Conflicted flag on the medium-tier IQ benefit strengthens the claim relative to the source review.
-
2.15 — Colloquial “fill the gap”: At-a-glance uses consumer-grade “fill the gap” instead of formal clinical phrasing for how hygiene, diet, and substitutes address the caries trade-off.
Fixes 10/08/2026 08:40
-
1.2 / 1.3 — Conflicted flag restored: Added “(conflicted)” to the medium-tier childhood IQ benefit text so it matches the ER’s cautious Conflicted marking.
-
2.15 — Formal trade-off phrasing: Replaced colloquial “mineral toothpaste substitutes fill the gap” with “fluoride-free remineralizing toothpaste maintain enamel protection” in at-a-glance (still 60 words).
Issues 10/08/2026 08:33
- 1.1 — At-a-glance overclaim: At-a-glance applies “case is strongest” to low iodine and reduced kidney function; ER Conclusion only uses that phrase for high baseline exposure and early brain development.
- 1.3 — Strengthened population claim: Same sentence upgrades low iodine and reduced kidney function from “keep total load modest” to “case is strongest.”
- 7.3 — Unsupported strongest-case fact: The at-a-glance fact listing low iodine and reduced kidney function under “case is strongest” lacks a supporting ER passage as worded.
Fixes 10/08/2026 08:34
- 1.1 / 1.3 / 7.3 — At-a-glance population claim: Rewrote the closing sentence so “case is strongest” applies only to high water fluoride and early brain development, and low iodine / reduced kidney function use ER’s “keep load modest” framing (trimmed “expected” to stay ≤60 words).
Issues 10/08/2026 08:23
-
1.3 — Tea condition dropped: Protocol action_3_value states “Moderate very high tea intake” without the ER’s condition “if urinary fluoride remains high” (Therapeutic Protocol, diet sources), which broadens the claim.
-
4.2 / 4.3 — Interaction labels paraphrased: Key Interactions list items rewrite ER bold labels instead of using them verbatim (e.g., “Iodine intake (caution / monitor)” → “Low iodine intake…”; “Fluoride dental products used concurrently (defeats avoidance)” → product list paraphrase; “reduced eGFR…” → “reduced kidney filtration / chronic kidney disease”).
Fixes 10/08/2026 08:23
-
1.3 — Tea condition restored: Set action_3_value to “Moderate very high tea if urinary fluoride remains high” (matching ER Therapeutic Protocol diet sources) and removed non-diet floss/rinse text from action_3_sub.
-
4.2 / 4.3 — Interaction labels restored: Replaced paraphrased Key Interactions items with ER bold labels (Iodine intake; Calcium, magnesium, and aluminum; High-fluoride foods and beverages; Fluoride dental products used concurrently; Kidney-impairing drugs and reduced eGFR…), preserving additive-exposure examples.
Issues 10/08/2026 08:19
- 1.3 — Softened protocol claims: action_2_sub softens the ER hybrid fluoride gate from “short supervised periods if a dentist documents high caries activity” to “optional short hybrid fluoride if high caries activity” (drops supervised/dentist documentation). action_3_value drops “very” from ER “Moderate very high-tea intake”.
- 7.4 — Specialist at-a-glance term: at_a_glance uses “remineralizing” (specialist dental jargon) instead of a plain-language alternative.
Fixes 10/08/2026 08:20
- 1.3 — Softened protocol claims: Restored action_2_sub to “short supervised fluoride if dentist documents high caries activity” (from the softened hybrid wording). Restored action_3_value to “Moderate very high tea intake”. Tightened at_a_glance trade-off wording to “higher expected cavity risk” to match the ER.
- 7.4 — Specialist at-a-glance term: Replaced “remineralizing toothpaste substitutes” with plain-language “mineral toothpaste substitutes” in at_a_glance.
Issues 10/08/2026 08:10
- 4.2 / 4.3 — Protocol labels not verbatim: Protocol action labels use abbreviated or invented text (“Water”, “Toothpaste”, “Diet & hygiene”) instead of the ER Therapeutic Protocol bold labels (“Water strategy”, “Toothpaste strategy”, “Diet sources”).
- 10.1 / 10.2 / 10.4 — Action 3 off Protocol: action_3_value centers “Reduce free-sugar frequency” and action_3_sub includes RO remineralization from Risk Mitigation, not the three primary Therapeutic Protocol implementation bullets (water, toothpaste, diet sources / other dental products).
Fixes 10/08/2026 08:12
- 4.2 / 4.3 — Protocol labels restored: Set action labels to ER Therapeutic Protocol bold labels: “Water strategy”, “Toothpaste strategy”, and “Diet sources” (replaced abbreviated/invented “Water”, “Toothpaste”, “Diet & hygiene”).
- 10.1 / 10.2 / 10.4 — Action 3 from Protocol: Replaced free-sugar / RO-remineralization content with Protocol-derived Diet sources: value “Moderate high-tea intake”; sub “Low-fluoride cooking water; fluoridated salt awareness; fluoride-free floss/rinse”.
Issues 10/08/2026 08:03
- 2.7 — Unexpanded medical jargon: Protocol uses “RO” without expansion; Key Interactions use “eGFR” and “CKD” without the expansions present in the ER.
- 2.15 — Colloquial cut/cuts: At-a-glance “cuts a non-essential mineral” and action_3_value “Cut free-sugar frequency” are consumer-grade; formal wording should use “reduces” / “Reduce”.
- 7.4 — Specialist hydroxyapatite term: At-a-glance uses “hydroxyapatite” instead of plain language (e.g., remineralizing toothpaste).
Fixes 10/08/2026 08:03
- 2.7 — Unexpanded medical jargon: Expanded protocol “RO” to “Reverse osmosis” / “reverse-osmosis”; replaced caution “eGFR / CKD” with “kidney filtration / chronic kidney disease”.
- 2.15 — Colloquial cut/cuts: Changed at-a-glance “cuts” to “reduces exposure to” and action_3_value “Cut free-sugar frequency” to “Reduce free-sugar frequency”.
- 7.4 — Specialist hydroxyapatite term: Replaced at-a-glance “hydroxyapatite” with plain-language “remineralizing toothpaste substitutes”.
Issues 10/08/2026 07:57
- 9.4 — Mechanistic interaction elaboration: The calcium, magnesium, and aluminum caution item ends with “(modestly lower fluoride absorption)”, which is mechanistic rationale rather than a concise key fact (QRS Key Interactions list).
- 9.5 — Severity parentheticals dropped: ER severity/type parentheticals are not preserved on several caution items: Ca/Mg/Al should keep “(mitigating)”; high-fluoride foods missing “(additive exposure)”; kidney item missing “(caution)”; concurrent fluoride products missing “(defeats avoidance)”.
Fixes 10/08/2026 07:57
- 9.4 — Mechanistic interaction elaboration: Replaced Ca/Mg/Al caution parenthetical “(modestly lower fluoride absorption)” with ER severity class “(mitigating)”.
- 9.5 — Severity parentheticals restored: Restored ER severity/type parentheticals on caution items: “(defeats avoidance)” on concurrent fluoride products; “(additive exposure)” on high-fluoride foods; “(caution)” on kidney-impairing drugs / reduced eGFR / CKD; “(mitigating)” on Ca/Mg/Al.